

Curriculum Vitae

Personal information Jan Bogaerts

Work experience

1. Employer: EORTC
 - Start date: 092024
 - End date:
 - Position: Scientific Advisor
 - Activities: Main responsibility is review of all EORTC Clinical Trial, Research Project outlines. Provide expertise for scientific activities. Support the Scientific Director in leading scientific activities at EORTC HQ.
 - Country: Belgium
2. Employer: EORTC
 - Start date: 102017
 - End date: 082024
 - Position: Scientific Director
 - Activities: Responsible for all EORTC HQ statistics, Medical Department, Translational Research and Quality of Life
 - Country: Belgium
3. Employer: EORTC
 - Start date: 042015
 - End date:
 - Position: Methodology Director
 - Activities: Responsible for all EORTC HQ statistics, Data Management and IT.
 - Country: Belgium
4. Employer: EORTC
 - Start date: 022012
 - End date: 032015
 - Position: Methodology Vice Director
 - Activities:
 - Country: Belgium
5. Employer: EORTC
 - Start date: 102010
 - End date: 022012
 - Position: Head of Statistics Department
 - Activities:
 - Country: Belgium
6. Employer: EORTC
 - Start date: 062006
 - End date: 102010
 - Position: Senior Statistician
 - Activities: Breast cancer group
 - Country: Belgium
7. Employer: EORTC
 - Start date: 032004
 - End date: 062006
 - Position: Statistician
 - Activities: Breast cancer group, Head and Neck cancer group
 - Country: Belgium
8. Employer: Bristol_Myers Squibb
 - Start date: 111993
 - End date: 022004
 - Position: Associate Director Statistics
 - Activities: Several positions held: Statistician, Senior Statistician, Principal Statistician,
 - Country: Belgium
9. Employer: Free University of Brussels
 - Start date: 101990
 - End date: 091993
 - Position: Assistant Mathematics, Statistics, Operations Research
 - Activities: Assistant in department of Sciences Teach exercise courses, research in Mathematics (PhD in topology, orders, continuity).
 - Country: Belgium
10. Employer: Free University of Brussels
 - Start date: 101986
 - End date: 081989
 - Position: Assistant Statistics, Operations Research
 - Activities: Assistant in department Economic, Social, Political Sciences. Teach exercise courses, some programming (Pascal, SPSS), research in Operations Research
 - Country: Belgium

Education and training

1. Subject: Free University of Brussels
 - Start date: 1990
 - End date: 1993

- Qualification: PhD Mathematics
 - Organisation:
 - Country: Belgium
2. Subject: Free University of Brussels
- Start date: 1986
 - End date: 1988
 - Qualification: Degree in Management
 - Organisation:
 - Country: Belgium
3. Subject: Free University of Brussels
- Start date: 1982
 - End date: 1986
 - Qualification: Degree in Mathematics
 - Organisation:
 - Country: Belgium

Additional information

Publications

- Wyatt AW, Litière S, Bidard FC, Cabel L, Dyrskjøt L, Karlovich CA, Pantel K, Petrie J, Philip R, Andrews HS, Vellanki PJ, Tolmeijer SH, Villalobos Alberu X, Alfano C, Bogaerts J, Calvo E, Chen AP, Toledo RA, de Vries EGE, Seymour L, Laurie SA, Garraza E. Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group. *Clin Cancer Res*. 2024 Sep 13.
- Puhr HC, Xenophontos E, Giraut A, Litière S, Boone L, Bogaerts J, Colienne M, Preusser M. Kidney function assessment for eligibility in clinical cancer trials - Data from the European Organisation for Research and Treatment of Cancer. *Eur J Cancer*. 2024 Oct;210:114302..
- Nakajima EC, Simpson A, Bogaerts J, de Vries EGE, Do R, Garalda E, Goldmacher G, Kinahan PE, Lambin P, LeStage B, Li Q, Lin F, Litière S, Perez-Lopez R, Petrick N, Schwartz L, Seymour L, Shankar L, Laurie SA. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group. *JCO Precis Oncol*. 2024 Apr;8:e2300687.
- Postmus D, Litière S, Bogaerts J, Versluis J, Cornelissen JJ, Pignatti F. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting. *Eur J Cancer*. 2024 Jan;197:113496.
- Lopes Cardozo JMN, Veira SE, Ait Hassou L, Uwimana AL, Božović-Spasojević I, Bogaerts J, Cardoso F, Schmidt MK, Rutgers EJT, Poncet C, Drukker CA. Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort. *Breast*. 2023 Oct;71:143-149.
- Saesen R, Van Hemelrijck M, Bogaerts J, Booth CM, Cornelissen JJ, Dekker A, Eisenhauer EA, Freitas A, Gronchi A, Hernán MA, Hulstaert F, Ost P, Szturz P, Verkooijen HM, Weller M, Wilson R, Lacombe D, van der Graaf WT. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. *Eur J Cancer*. 2023 Jun;186:52-61.
- Shankar LK, Huang E, Litière S, Hoekstra OS, Schwartz L, Collette S, Boellaard R, Bogaerts J, Seymour L, deVries EGE. Meta-Analysis of the Test-Retest Repeatability of [18F]- Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response. *Clin Cancer Res*. 2023 Jan 4;29(1):143-153.
- Litière S, Bogaerts J. Imaging endpoints for clinical trial use: a RECIST perspective. *J Immunother Cancer*. 2022 Nov;10(11):e005092. doi: 10.1136/jitc-2022-005092. PMID: 36424032.
- Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causseret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppi G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. *Lancet Oncol*. 2021 Apr;22(4):476-488. doi: 10.1016/S1470-2045(21)00007-3. PMID: 33721561.
- Jacob L, Witteveen A, Beumer I, Delahaye L, Wehkamp D, van den Akker J, Snel M, Chan B, Floore A, Bakx N, Brink G, Poncet C, Bogaerts J, Delorenzi M, Piccart M, Rutgers E, Cardoso F, Speed T, van't Veer L, Glas A. Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. *Commun Biol*. 2020 Jul 27;3(1):397. doi: 10.1038/s42003-020-1111-1. PMID: 32719399.
- Delaloge S, Piccart M, Rutgers E, Litière S, van 't Veer LJ, van den Berkmoortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghachian M, Smilde TJ, Thompson AM, Viale G, Zoppi G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F; MINDACT investigators and the TRANSBIG Consortium. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. *J Clin Oncol*. 2020 Apr 10;38(11):1186-1197. doi: 10.1200/JCO.19.01371. PMID: 32083990.
- Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney J, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. *Eur J Cancer*. 2019 Jun;114:128-136. doi: 10.1016/j.ejca.2019.03.025. Epub 2019 May 3. PMID: 31060925.
- Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancy J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekas S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. *J Clin Oncol*. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12. PMID: 30860949.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet*. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8. PMID: 30739743.
- Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. *J Clin Oncol*. 2019 Feb 1;37(4):336-349. doi: 10.1200/JCO.18.00729. Epub 2018 Dec 17. PMID: 30707056.
- Lacombe D, Bogaerts J, Tombal B, Maignan F, Osipenko L, Sullivan R, Gofinopoulos V. Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society. *Mol Oncol*. 2019 Mar;13(3):558-566. doi: 10.1002/1878-0261.12431. Epub 2019 Jan 19. Review. PMID: 30561901.
- Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. *J Natl Cancer Inst*. 2018 Oct 1;110(10):1142-1143. doi: 10.1093/jnci/djy029. No abstract available. PMID: 29546378.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. *Lancet Oncol*. 2018 Jan;19(1):27-39. doi: 10.1016/S1470-2045(17)30777-5. Epub 2017 Dec 11. PMID: 29242041.
- Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart MJ, de Vries EGE, Latino NJ, Douillard JY, Cherny NI. Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. *ESMO Open*. 2017 Oct 9;2(4):e000216. doi: 10.1136/esmoopen-2017-000216. eCollection 2017. PMID: 29067214.

20. Kempf E, Bogaerts J, Lacombe D, Liu L. 'Mind the gap' between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research. *Eur J Cancer*. 2017 Nov;86:143-149. doi: 10.1016/j.ejca.2017.08.028. Epub 2017 Oct 4. PMID: 28987771.
21. Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty. Societal challenges of precision medicine: Bringing order to chaos. *Eur J Cancer*. 2017 Oct;84:325-334. doi: 10.1016/j.ejca.2017.07.028. Epub 2017 Sep 4. PMID: 28865260.
22. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. *N Engl J Med*. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: *N Engl J Med*. 2017 Aug 17;377(7):702. PMID: 28581356.
23. Thong MSY, Kicinski M, Coens C, Giusti F, van de Poll-Franse L, Bogaerts J, Liu L. A population-based approach to compare patient-reported outcomes of long-term Hodgkin's lymphoma survivors according to trial participation: a joint study from the Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship registry and European Organisation for Research and Treatment of Cancer. *Eur J Cancer Prev*. 2017 Sep;26:Joining forces for better cancer registration in Europe:S223-S228. doi: 10.1097/CEJ.0000000000000381. PMID: 28574866.
24. Vandenberghe S, Duchateau L, Slaets L, Bogaerts J, Vansteelandt S. Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques. *Stat Methods Med Res*. 2018 Nov;27(11):3367-3385.
25. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekas S, Lin NU, Litière S, Dancy J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncol*. 2017 Mar;18(3):e143-e152. Review. PubMed PMID: 28271869.
26. Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST – learning from the past to build the future. *Nat Rev Clin Oncol*. 2017 Mar;14(3):187-192. Review. PubMed PMID: 27995946.
27. Ditttrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmolli HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016ESMO Open. 2016 Sep 29;1(5):e000097. Review. PMID: 27843641.
28. Liu L, Giusti F, Schaapveld M, Aleman B, Lugtenburg P, Meijnders P, Hutchings M, Lemmens V, Bogaerts J, Visser O. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up. *Br J Haematol*. 2016 Oct 21. doi: 10.1111/bjh.14379. [Epub ahead of print] PMID: 27766636.
29. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Goulinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghathian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernardis R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.. 70-Genie Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med*. 2016 Aug 25;375(8):717-29. PMID: 27557300.
30. Ditttrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. *Ann Oncol*. 2016 Aug;27(8):1378-81. PMID: 27457308.
31. Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekas S, Shankar L, Bogaerts J, Chen A, Dancy J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. *Eur J Cancer*. 2016 May 26.
32. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekas S, Shankar L, Bogaerts J, Chen A, Dancy J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L. RECIST 1.1-Update and clarification: From the RECIST committee. *Eur J Cancer*. 2016 May 14.
33. Viale G, Slaets L, de Snoo FA, Bogaerts J, Russo L, Van't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Dell'Orto P, Glas AM, Cardoso F. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. *Breast Cancer Res Treat*. 2016 Feb;155(3):463-9.
34. Tryfonidis K, Basaran G, Bogaerts J, Debléd M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart M, Cameron D; EORTC-Breast Cancer Group. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). *Eur J Cancer*. 2015 Dec 24;53:144-154. doi: 10.1016/j.ejca.2015.10.012. [Epub ahead of print] PubMed PMID: 26724641.
35. An MW, Han Y, Meyers JP, Bogaerts J, Sargent DJ, Mandrekas SJ. Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. *J Clin Oncol*. 2015 Dec 1;33(34):4048-57. doi: 10.1200/JCO.2015.60.8778. Epub 2015 Oct 26. PubMed PMID: 26503199; PubMed Central PMCID: PMC4669590.
36. An MW, Dong X, Meyers J, Han Y, Grothey A, Bogaerts J, Sargent DJ, Mandrekas SJ; Response Evaluation Criteria in Solid Tumors Steering Committee. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. *J Natl Cancer Inst*. 2015 Aug 21;107(11). pii: djv239. doi: 10.1093/jnci/djv239. Print 2015 Nov. PubMed PMID: 26296640; PubMed Central PMCID: PMC4643633.
37. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. *Eur J Cancer*. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24. Review. PubMed PMID: 25542058; PubMed Central PMCID: PMC4639696.
38. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagel DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol*. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15. PubMed PMID: 25439688.
39. Lacombe D, Burock S, Bogaerts J, Schoeffski P, Goulinopoulos V, Stupp R. The dream and reality of histology agnostic cancer clinical trials. *Mol Oncol*. 2014 Sep 12;8(6):1057-63. PubMed PMID: 25349876.
40. Fumoleau P, Koch KM, Brain E, Lokiec F, Rezaei K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marréaud S, Cardoso F. A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). *Breast*. 2014 Oct;23(5):663-9. doi: 10.1016/j.breast.2014.07.003. Epub 2014 Jul 24. PMID: 25065668.
41. Litière S, de Vries EG, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST Committee. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1

database. Eur J Cancer. 2014 Jul;50(10):1847-53. doi: 10.1016/j.ejca.2014.03.014. Epub 2014 Apr 10. PMID: 24726734.

42. Mandrekar SJ, An MW, Meyers J, Grothey A, Bogaerts J, Sargent DJ. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. J Clin Oncol. 2014 Mar 10;32(8):841-50. doi: 10.1200/JCO.2013.52.3019. Epub 2014 Feb 10. PMID: 24516033.

43. Liu Y, Litière S, de Vries EG, Sargent D, Shankar L, Bogaerts J, Seymour L. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer. 2014 Jan;50(2):260-6. doi: 10.1016/j.ejca.2013.10.011. Epub 2013 Nov 13. PMID: 24239447.

44. Senkus E, Gomez H, Dirix L, Jerusalem G, Murray E, Van Tienhoven G, Westenberg AH, Bottomley A, Rapon J, Bogaerts J, Di Leo A, Nešković-Konstantinović Z. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology. 2014 Feb;23(2):173-82. doi: 10.1002/pon.3384. Epub 2013 Aug 29. PMID: 24038775.

45. Senkus E, Gomez H, Dirix L, Jerusalem G, Murray E, Van Tienhoven G, Westenberg AH, Bottomley A, Rapon J, Bogaerts J, Di Leo A, Nešković-Konstantinović Z. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology. 2013 Aug 29. doi: 10.1002/pon.3384. [Epub ahead of print] PMID: 24038775.

46. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013 May 20;31(15):1834-41. doi: 10.1200/JCO.2012.45.3639. Epub 2013 Apr 15. Review. PMID: 23589555.

47. Bonnefoi H, Zaman K, Debled M, Fiche M, Fournier M, Nobahar M, Pierga JY, Koch KM, Bartlett J, Zimmer A, Marreaud S, Bogaerts J, Cameron D. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer. Eur J Cancer. 2013 Jan;49(2):281-9. doi: 10.1016/j.ejca.2012.08.006. Epub 2012 Sep 18. PMID: 22999386.

48. Lalami Y, Specenier PM, Awada A, Lacombe D, Liberatoscioli C, Fortpied C, El-Hariry I, Bogaerts J, Andry G, Langendijk JA, Vermorken JB. EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiother Oncol. 2012 Nov;105(2):238-40. PubMed PMID 22989664.

49. Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H. 2.Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012 Apr;13(4):412-9. PubMed PMID:22373563.

50. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delalogue S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. Eur J Cancer. 2011 Dec;47(18):2742-9. PubMed PMID:22051734.

51. Fortpied C, Liberatoscioli C, Bogaerts J. Design issues in head and neck clinical trials: a statistician's perspective. Anticancer Drugs. 2011 Aug;22(7):682-7. Review. PubMed PMID: 21709617.

52. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol. 2011 Jun;12(6):527-39. Epub 2011 May 11. PubMed PMID: 21570352.

53. Sinacki M, Badzio A, Welnicka-Jaskiewicz M, Bogaerts J, Piccart MJ, Therasse P, Smith IE, Hatschek T, Jassem J. Pattern of care in locally advanced breast cancer: focus on local therapy. Breast. 2011 Apr;20(2):145-50. Epub 2010 Sep 25. PubMed PMID: 20870406.

54. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapon J, Allgeier A, Bogaerts J, Lacombe D. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer. 2010 Aug;46(12):2206-15. Epub 2010 May 13. PubMed PMID: 20471824.

55. Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijn JH, Westenberg HA, van der Mijle H, Snoij M, Hurkmans C, Rutgers EJ. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010 Jul;17(7):1854-61. Epub 2010 Mar 19. PubMed PMID: 20300966; PubMed Central PMCID: PMC2889289.

56. van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JN, Lambiase A, Bordignon C, Punt CJ, Heerschap A, van Herpen CM. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res. 2010 Feb 15;16(4):1315-23. Epub 2010 Feb 9. PubMed PMID: 20145168.

57. Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Cataliotti L, Klinkenbijn J, Westenberg HA, van der Mijle H, Hurkmans C, Rutgers EJ. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol. 2010 Feb 10;28(5):731-7. Epub 2009 Dec 28. PubMed PMID: 20038733; PubMed Central PMCID: PMC2834391.

58. Michiels S, Le Maître A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, Bourhis J, Pignon JP; MARCH and MACH-NC Collaborative Groups. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009 Apr;10(4):341-50. Epub 2009 Feb 24. PubMed PMID: 19246242.

59. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009 Jan;15(1):68-74. Epub 2009 Jan 4. Erratum in: Nat Med. 2009 Feb;15(2):220. Wirapati, Pratyaksha [corrected to Wirapati, Pratyaksha]. PubMed PMID: 19122658.

60. Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P; RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 2009 Jan;45(2):248-60. Epub 2008 Dec 16. PubMed PMID: 19095437.

61. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

62. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008 Oct 20;26(30):4883-90. Epub 2008 Sep 15. PubMed PMID: 18794551; PubMed Central PMCID: PMC2652082.

63. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2009 Jul;116(2):295-302. Epub 2008 Jul 27. PubMed PMID: 18661261.

64. van Nes JG, Putter H, Julien JP, Tubiana-Hulin M, van de Vijver M, Bogaerts J, de Vos M, van de Velde CJ; Cooperating Investigators of the EORTC. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009 May;115(1):101-13. Epub 2008 May 18. PubMed PMID: 18484198.

65. Pajak B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008 Apr;17(2):180-5. Epub 2007 Oct 31. PubMed PMID: 17976988.

66. Demonty G, Bogaerts J. PACS 01 trial: questions about patients' characteristics and reported results. J Clin Oncol. 2007 May 20;25(15):2143; author reply 2143-4. PubMed PMID: 17513826.

67. Yun HJ, Bogaerts J, Awada A, Lacombe D. Clinical trial design limitations in head and neck squamous cell carcinomas. *Curr Opin Oncol*. 2007 May;19(3):210-5. Review. PubMed PMID: 17414638.
68. Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group; Scottish Breast Cancer Trials Group. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. *Eur J Cancer*. 2007 Jan;43(2):331-40. Epub 2006 Nov 28. PubMed PMID: 17134892.
69. Biganzoli L, Coleman R, Minisini A, Hamilton A, Aapro M, Therasse P, Mottino G, Bogaerts J, Piccart M. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. *Crit Rev Oncol Hematol*. 2007 Jan;61(1):84-9. Epub 2006 Nov 20. PubMed PMID: 17116400.
70. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. *Nat Clin Pract Oncol*. 2006 Oct;3(10):540-51. Review. PubMed PMID: 17019432.
71. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *J Natl Cancer Inst*. 2006 Sep 6;98(17):1183-92. PubMed PMID: 16954471.
72. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeek I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *J Clin Oncol*. 2006 Jul 20;24(21):3381-7. Epub 2006 Jun 26. PubMed PMID: 16801628.

Projects RECIST working group.

Memberships ESMO MCBS committee member.

Other Relevant Information Reviewer for several funding committees in Belgium and the Netherlands.